The Basel & IOSCO committees’ final text on margin requirements for non-centrally cleared derivatives, BCBS 317, mandates the posting of Initial Margin between bilateral OTC counterparties. With a 4-year phase-in period through to 2020, the largest banks started exchanging Initial Margin in September 2016.
Complete out-of-the-box solution
MX.3 provides a comprehensive pre-packaged solution for Bilateral Initial Margin for easy and timely deployment. Uniquely, MX.3 can generate the risk sensitivities for all non-cleared OTC derivatives, which can be combined with externally-fed risk sensitivities for some asset classes, if required. These are mapped to the appropriate SIMM™ buckets for eligible trades and products, as per the collateral agreement data. MX.3 calculates SIMM™ and generates CRIF files, which can be shared with third parties via the Acadiasoft connector and/or directly generate IM margin calls within MX.3.
Smooth regulatory approval pathway
MX.3 for Bilateral Initial Margin eases the regulatory approval pathway with comprehensive support for back-testing Initial Margin calculations.
If you wish to learn more about our Bilateral Initial Margin solution, please download the flyer here.